Bluebird Bio Beats Investors’ Sickle Cell Therapy Timeline Suit

Bluebird Bio Inc. is free of a securities suit claiming it made misleading statements about the approval timeline for new sickle cell disease treatment LentiGlobin after a federal judge in Massachusetts said investors failed to allege falsity or intent.

Investors’ would-be class complaint fell short of alleging the biotechnology company intentionally or recklessly made any false or misleading statements about its new gene therapy that caused their losses, the U.S. District Court for the District of Massachusetts said, dismissing the case without leave to amend.

The investors argued that Bluebird “intentionally or recklessly disregarded” that a comparability plan couldn’t ...